E. Steve Woodle, MD, FACS received his under graduate degree at Texas A&M University and his medical degree from the University of Texas Medical Branch. He completed fellowships in kidney and pancreas transplantation as well as liver transplantation and hepatobiliary surgery at the University of Chicago, and was an NIH Surgical Research Fellow at both the University of California-Davis and at the University of Chicago.
Dr. Woodle is a member of over 30 scientific and professional societies, including the American Surgical Association. He has chaired committees in the American Society of Transplantation and has served on the Board of Directors of the American Society of Transplantation.
Dr. Woodle has published over 300 scientific articles and 20 book chapters in the field of transplantation. He has been the recipient of NIH research grants in immunobiology and has received a Clinician Scientist Research Award from the American Heart Association. Dr. Woodle has served on several NIH study sections, and several FDA Committees that regulate immunosuppressive drug approval. He has also served on trial design committees for a number of multicenter studies, and has served as lead investigator in several multicenter trials. Dr. Woodle has made seminal contributions in the areas of immunosuppressive drug development, having introduced teplizumab and bortezomib as immunosuppressive agents in the transplant field.
His research currently focuses on development of plasma cell targeted therapies, innovative immunosuppresion regimens with costimulatory blockade, corticosteroid elimination, kidney exchange programs and posttransplant malignancies.
Dr. Woodle's clinical activities are focused on kidney transplantation, with particular emphasis on living donor kidney transplantation. Dr. Woodle initiated the Sensitized Patient Program and Clinics, which he currently continues to lead and staff.
{{comment.mentionTime}}